The price of Angiodynamic Inc (NASDAQ:ANGO) shares last traded on Wall Street rose 2.98% to $5.87.
ANGO stock price is now 1.22% away from the 50-day moving average and -20.09% away from the 200-day moving average. The market capitalization of the company currently stands at $233.98M.
With the price target of $19, H.C. Wainwright recently initiated with Buy rating for Angiodynamic Inc (NASDAQ: ANGO). On April 17, 2023, Raymond James Downgraded its previous ‘Strong Buy’ rating to ‘Outperform’ on the stock reducing its target price from $14 to quote $13, while ‘Canaccord Genuity’ rates the stock as ‘Buy’
A total of 3.23% of the company’s stock is owned by insiders.
During the past 12 months, Angiodynamic Inc has had a low of $5.26 and a high of $12.62. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 2.38, and a quick ratio of 1.55. The fifty day moving average price for ANGO is $5.80 and a two-hundred day moving average price translates $7.35 for the stock.
The latest earnings results from Angiodynamic Inc (NASDAQ: ANGO) was released for Nov, 2023. According to the Medical Instruments & Supplies Company, earnings per share came in at -$0.05, beating analysts’ expectations of -$0.07 by 0.02. This compares to -$0.21 EPS in the same period last year. The net profit margin was -4.28% and return on equity was -3.49% for ANGO. The company reported revenue of $79.07 million for the quarter, compared to $85.43 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -7.44 percent. For the current quarter, analysts expect ANGO to generate $75.73M in revenue.
Angiodynamic Inc(ANGO) Company Profile
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company’s thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
